Olmutinib |
| Catalog No.GC19270 |
Olmutinib (HM61713; BI-1482694) is an irreversible EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1353550-13-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Olmutinib (HM61713; BI-1482694) is an irreversible EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain.
Olmutinib potently inhibits EGFR in HCC827 cells expressing EGFRDEL19 (IC50=9.2 nM) and H1975 cells expressing EGFRL858R/T790M (IC50=10 nM). In contrast, the IC50 of olmutinib against cells expressing EGFRWT is 2225 nM[1].
References:
[1]. Kim ES, et al. Olmutinib: First Global Approval. Drugs.2016 Jul;76(11):1153-7.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *